Drugs / Inactivated SARS-CoV-2 vaccine (Vero cell)
Inactivated SARS-CoV-2 vaccine (Vero cell)
also known as
SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT04917523 | Jul 2021 → Mar 2022 | COVID-19, pneumonia | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT04659239 | Jan → Sep 2021 | COVID-19 | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT04560881 | Sep 2020 → Dec 2021 | COVID-19 | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 3 | NCT04612972 | Sep 2020 → Feb 2021 | COVID-19 | Universidad Peruana Cayetano Heredia | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05112913 | Jul → Nov 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated SARS-CoV-2 Vaccine (Vero cell) | “Inactivated SARS-CoV-2 vaccine (Vero cell); 200WU/dose for per human use” NCT04612972 ↗ |
| Known as | SARS-CoV-2 Vaccine (Vero Cell), Inactivated | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04917523 ↗ |
| Modality | Vaccine | “inactivated SARS-CoV-2 vaccine (Vero cell)” NCT04560881 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT04560881 ↗ |